Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$37.47

0.18 (0.48%)

17:34
10/02/18
10/02
17:34
10/02/18
17:34

Biohaven Pharmaceutical files to sell 109,523 common shares for holders

  • 11

    Oct

  • 12

    Oct

  • 27

    Nov

BHVN Biohaven Pharmaceutical
$37.47

0.18 (0.48%)

08/16/18
PIPR
08/16/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven Pharmaceutical shares worth 'significantly more,' says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $48 price target on Biohaven shares, telling investors in a research note that with the recent favorable and non-dilutive Royalty Pharma deal, Biohaven is now well funded through the end of 2019 when the rimegepant NDA for the treatment of acute migraine should be well under review. By the end of the year, he believes the rimegepant ODT data will be positive, potentially providing another layer of differentiation. Overall, Van Buren believes Biohaven shares are worth "significantly more."
08/23/18
CANT
08/23/18
NO CHANGE
Target $55
CANT
Overweight
Biohaven Pharmaceutical transferred with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan took over coverage of Biohaven Pharmaceutical with an Overweight rating and $55 price target. The analyst sees Biohaven's rimegepant in acute migraine as the key driver of shareholder value.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
09/12/18
PIPR
09/12/18
NO CHANGE
Target $65
PIPR
Overweight
Biohaven Pharmaceutical price target raised to $65 from $48 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Biohaven Pharmaceutical to $65 citing higher conviction in migraine. After speaking with management and key opinion leaders, the analyst has an "even higher level of conviction" in Biohaven's migraine franchise. He believes rimegepant could achieve $1B-plus in peak sales in acute migraine in the U.S. Further, Van Buren estimates the opportunity in migraine prevention could add another $1B-plus in peak sales. In addition, Biohaven has four other central nervous candidates candidates progressing through the clinic that will soon generate value for shareholders, the analyst tells investors in a research note. He recommends buying shares of Biohaven Pharmaceutical at current levels and keeps an Overweight rating on the name.

TODAY'S FREE FLY STORIES

FND

Floor & Decor

$37.71

0.93 (2.53%)

11:54
02/21/19
02/21
11:54
02/21/19
11:54
Recommendations
Floor & Decor analyst commentary  »

Floor & Decor target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

AGI

Alamos Gold

$4.84

-0.03 (-0.62%)

11:50
02/21/19
02/21
11:50
02/21/19
11:50
Options
Alamos Gold attracts calls sold after an analyst downgrade »

Alamos Gold attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MDT

Medtronic

$92.39

-0.41 (-0.44%)

11:46
02/21/19
02/21
11:46
02/21/19
11:46
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

S

Sprint

$6.43

0.115 (1.82%)

11:45
02/21/19
02/21
11:45
02/21/19
11:45
Options
Sprint call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 11

    Mar

  • 11

    Mar

BIIB

Biogen

$322.54

-12.47 (-3.72%)

, RHHBY

Roche

$0.00

(0.00%)

11:44
02/21/19
02/21
11:44
02/21/19
11:44
On The Fly
Biogen downgrade, cannabis sector initiation among today's top analyst calls »

Check out today's top…

BIIB

Biogen

$322.54

-12.47 (-3.72%)

RHHBY

Roche

$0.00

(0.00%)

X

U.S. Steel

$24.06

0.06 (0.25%)

AAN

Aaron's

$53.84

0.2 (0.37%)

BBY

Best Buy

$60.11

-0.15 (-0.25%)

DHI

D.R. Horton

$39.76

-0.11 (-0.28%)

LEN

Lennar

$48.81

-0.15 (-0.31%)

APHA

Aphria

$10.33

0.17 (1.67%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$5.89

-0.09 (-1.51%)

CGC

Canopy Growth

$45.25

-0.93 (-2.01%)

ACB

Aurora Cannabis

$7.07

0.01 (0.14%)

TLRY

Tilray

$79.49

-1.58 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 05

    Mar

  • 05

    Mar

  • 06

    Mar

  • 11

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 04

    Apr

  • 28

    May

  • 19

    Aug

MNSB

MainStreet Bancshares

$0.00

(0.00%)

11:42
02/21/19
02/21
11:42
02/21/19
11:42
Hot Stocks
MainStreet Bancshares applies to list common stock on NASDAQ Capital Market »

MainStreet Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZSAN

Zosano Pharma

$4.19

1.98 (89.59%)

11:40
02/21/19
02/21
11:40
02/21/19
11:40
Recommendations
BTIG boosts Zosano target to $19 on 'solid' migraine safety data »

BTIG analyst Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

UNIT

Uniti Group

$11.23

-1.035 (-8.44%)

11:35
02/21/19
02/21
11:35
02/21/19
11:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 11

    Mar

  • 11

    Mar

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:32
02/21/19
02/21
11:32
02/21/19
11:32
Hot Stocks
Breaking Hot Stocks news story on Zosano Pharma »

Zosano Pharma jumps 100%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Conference/Events
UBS leisure/lodging analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zosano says Qtrypta long-term study shows 'well-tolerated safety profile' »

Zosano Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$4.85

-0.05 (-1.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zynerba patent listed by World Intellectual Property Organization »

The patent listed by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$24.23

-0.45 (-1.82%)

11:25
02/21/19
02/21
11:25
02/21/19
11:25
Options
JD.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    Mar

  • 20

    Mar

KMTUY

Komatsu

$0.00

(0.00%)

11:21
02/21/19
02/21
11:21
02/21/19
11:21
Downgrade
Komatsu rating change  »

Komatsu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
02/21/19
02/21
11:20
02/21/19
11:20
General news
Treasury announced $113 B in shorter dated coupon sales for next week »

Treasury announced $113 B…

SCI

Service Corp.

$42.31

-0.42 (-0.98%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Hot Stocks
Service Corp. raises quarterly cash dividend 6% to 18c per share »

Service Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/21/19
02/21
11:16
02/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

GS

Goldman Sachs

$197.12

-1.49 (-0.75%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Initiation
Goldman Sachs initiated  »

Odeon's Dick Bove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DK

Delek US

$36.95

-0.13 (-0.35%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Options
Delek US draws upside call buyers as shares slip off early highs »

Delek US draws upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.